Explore

Trendline Trendline
Veristat to Acquire Certara's Regulatory and Medical Writing Business, Enhancing Regulatory Services

Veristat to Acquire Certara's Regulatory and Medical Writing Business, Enhancing Regulatory Services

Veristat to Acquire Certara's Regulatory and Medical Writing Business, Enhancing Regulatory Services
Trendline Trendline
Replimune Layoffs in Massachusetts Following FDA Rejection of Melanoma Drug

Replimune Layoffs in Massachusetts Following FDA Rejection of Melanoma Drug

Replimune Layoffs in Massachusetts Following FDA Rejection of Melanoma Drug
Trendline Trendline
Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study

Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study

Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study
Trendline Trendline
Alcami Expands Global Reach with Acquisition of Tjoapack

Alcami Expands Global Reach with Acquisition of Tjoapack

Alcami Expands Global Reach with Acquisition of Tjoapack
Trendline Trendline
Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition

Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition

Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition
Trendline Trendline
Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions
Trendline Trendline
Gilead and Arcus End Cancer Drug Trials Following Futility Analysis

Gilead and Arcus End Cancer Drug Trials Following Futility Analysis

Gilead and Arcus End Cancer Drug Trials Following Futility Analysis
Trendline Trendline
AbCellera to Present Phase 1 Clinical Data for ABCL635 in Upcoming Earnings Call

AbCellera to Present Phase 1 Clinical Data for ABCL635 in Upcoming Earnings Call

AbCellera to Present Phase 1 Clinical Data for ABCL635 in Upcoming Earnings Call
Trendline Trendline
Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics
Trendline Trendline
UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment

UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment

UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment
Trendline Trendline
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Paving Way for Market Approval

AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Paving Way for Market Approval

AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Paving Way for Market Approval
Trendline Trendline
Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases

Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases

Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases